Cytotoxic T Lymphocytes
Phase 1Completed 0 watching 0 views this week๐ค Quiet
25
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Covid19
Conditions
Covid19
Trial Timeline
Sep 15, 2021 โ Jan 19, 2023
NCT ID
NCT04765449About Cytotoxic T Lymphocytes
Cytotoxic T Lymphocytes is a phase 1 stage product being developed by Tevogen Bio for Covid19. The current trial status is completed. This product is registered under clinical trial identifier NCT04765449. Target conditions include Covid19.
Hype Score Breakdown
Clinical
10
Activity
5
Company
2
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04765449 | Phase 1 | Completed |
Competing Products
20 competing products in Covid19